473 related articles for article (PubMed ID: 32224379)
21. Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020).
Lenci E; Cosottini L; Trabocchi A
Expert Opin Ther Pat; 2021 Jun; 31(6):509-523. PubMed ID: 33487088
[No Abstract] [Full Text] [Related]
22. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
23. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors.
Yamahana H; Komiya Y; Takino T; Endo Y; Yamada H; Asada C; Uto Y
Chem Pharm Bull (Tokyo); 2021; 69(10):1017-1028. PubMed ID: 34602570
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.
Stellas D; Patsavoudi E
Anticancer Agents Med Chem; 2012 Sep; 12(7):707-17. PubMed ID: 22292747
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.
Scannevin RH; Alexander R; Haarlander TM; Burke SL; Singer M; Huo C; Zhang YM; Maguire D; Spurlino J; Deckman I; Carroll KI; Lewandowski F; Devine E; Dzordzorme K; Tounge B; Milligan C; Bayoumy S; Williams R; Schalk-Hihi C; Leonard K; Jackson P; Todd M; Kuo LC; Rhodes KJ
J Biol Chem; 2017 Oct; 292(43):17963-17974. PubMed ID: 28860188
[TBL] [Abstract][Full Text] [Related]
26. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
Shoari A; Rasaee MJ; Kanavi MR; Daraei B
J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases: new directions toward inhibition in the fight against cancers.
King SE
Future Med Chem; 2016; 8(3):297-309. PubMed ID: 26910530
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
[TBL] [Abstract][Full Text] [Related]
29. Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors.
Khalil HH; El-Sheshtawy MM; Khattab SN; Abu-Serie MM; Shehat MG; Teleb M; Haiba NS
Bioorg Chem; 2024 Mar; 144():107155. PubMed ID: 38306827
[TBL] [Abstract][Full Text] [Related]
30. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
31. The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.
Li Z; Wei J; Chen B; Wang Y; Yang S; Wu K; Meng X
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175113
[TBL] [Abstract][Full Text] [Related]
32. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
33. A fragment-based exploration of diverse MMP-9 inhibitors through classification-dependent structural assessment.
Baidya SK; Banerjee S; Ghosh B; Jha T; Adhikari N
J Mol Graph Model; 2024 Jan; 126():108671. PubMed ID: 37976979
[TBL] [Abstract][Full Text] [Related]
34. Identification of matrix metalloproteinase inhibitors by chemical arrays.
Kawatani M; Fukushima Y; Kondoh Y; Honda K; Sekine T; Yamaguchi Y; Taniguchi N; Osada H
Biosci Biotechnol Biochem; 2015; 79(10):1597-602. PubMed ID: 25988721
[TBL] [Abstract][Full Text] [Related]
35. Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies.
Amar S; Fields GB
Expert Rev Proteomics; 2015; 12(5):445-7. PubMed ID: 26174966
[TBL] [Abstract][Full Text] [Related]
36. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
37. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
38. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
39. MMP-9 directed shRNAs as relevant inhibitors of matrix metalloproteinase 9 activity and signaling.
Nowak E; Galilejczyk A; Sypniewski D; Bednarek I
Postepy Hig Med Dosw (Online); 2013 Aug; 67():742-9. PubMed ID: 24018440
[TBL] [Abstract][Full Text] [Related]
40. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study.
Vandooren J; Knoops S; Aldinucci Buzzo JL; Boon L; Martens E; Opdenakker G; Kolaczkowska E
PLoS One; 2017; 12(4):e0174853. PubMed ID: 28369077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
